Antiviral T-cell Biofactory platform for SARS-CoV-2
Marvin A. Ssemadaali, Sherri L. Newmyer, Harikrishnan Radhakrishnan, Juan Arredondo, Harold S. Javitz, Satya Dandekar, Parijat Bhatnagar
This paper describes the development of a T-cell Biofactory platform that produces IFNs in response to SARS-CoV-2 infection, with analysis of its prophylactic and therapeutic effects and safety.
bioRxiv · Jun 26, 2022 · PreprintSynthetic Biology